Kay Bross Named Program Director, Member & Vendor Relations, SAFE-BioPharma Association

Kay Bross Named Program Director, Member & Vendor Relations, SAFE-BioPharma Association

FT. LEE, N.J.--(BUSINESS WIRE)--Mar 9, 2010 - Kay Bross has been named Program Director, Member and Vendor Relations for SAFE-BioPharma Association, the non-profit association that created and manages the SAFE-BioPharma® digital identity and digital signature standard for the pharmaceutical and healthcare industries.

Ms. Bross, who served as a member of the association's Board of Directors, is responsible for building and managing relationships with the association's growing member and vendor-partner communities. She also is responsible for business development and alliance management. SAFE-BioPharma members include many of the world's largest biopharmaceutical companies and, increasingly, smaller companies that want to benefit from the time and cost-saving efficiencies of the SAFE-BioPharma standard.

"We are fortunate that Kay Bross is available at this point in the association's development. As a former member of our board and someone who understands both the standard and the community it serves, she will be a valuable asset to the association's development," said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association.

Kay Bross is an authority in the area of electronic document management (EDM). She recently retired from Procter & Gamble, where she managed operations associated with Regulatory submissions data and developed the company's corporate intranet virtual library. As a member of P&G's Global Business Solutions, Information Security unit, she introduced the SAFE-BioPharma standard.

Ms. Bross also is recognized in the international EDM community. She co-chaired several annual Drug Information Association (DIA) Electronic Document Management Conferences and served on numerous DIA program committees. She is a frequent EDM speaker and panelist. She has served as a member of the SAFE-BioPharma Board of Directors.

Ms. Bross holds an MEd from Xavier University, Cincinnati and a BA from Emporia State University, Emporia, Ks.

About SAFE-BioPharma Association (www.safe-biopharma.org) SAFE-BioPharma Association is the non-profit association that created and manages the SAFE-BioPharma® digital identity and signature standard for the pharmaceutical and healthcare industries. It provides users with a secure, enforceable, and regulatory compliant way to verify identities of parties involved in electronic transactions and to apply digital signatures to electronic documents.

The Association's members include:

 

    * Abbott (NYSE: ABT)
    * Amarin Corp. (NASDAQ: AMRN)
    * Amgen (NASDAQ: AMGN)
    * AstraZeneca (NYSE: AZN)
    * Bristol-Myers Squibb (NYSE: BMY)
    * GlaxoSmithKline (NYSE: GSK)
    * Johnson & Johnson (NYSE: JNJ)
    * Eli Lilly (NYSE: LLY)
    * McDougall Scientific
    * Merck (NYSE: MRK)
    * MWB Consulting Limited
    * National Notary Association
    * Novartis (NYSE: NVS)
    * Oxford Outcomes
    * Pfizer (NYSE: PFE)
    * Premier Inc.
    * Roche
    * Sanofi-Aventis (NYSE: SNY)
    * ScheringPlough-Organon (NYSE: SGP)
    * SNAP Diagnostics

SAFE-BioPharma® is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.

Contact: SAFE-BioPharma Association
Jon Weisberg
M 801-860-9977
O 801-359-9977
[email protected]

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.